Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,872 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05984810RecruitingPhase 2
Using a glowing dye to help see pancreatic cancer during surgery
This trial tests whether a special dye (SGM-101) can help surgeons see remaining cancer cells during surgery for pancreatic cancer that has been treated before surgery. It may lead to more complete removal of the tumor.
LeidenAges 18 years+ - NCT06430437RecruitingPhase 3
Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT06764680RecruitingPhase 2
Oral drugs and radiation for advanced colorectal cancer after standard therapy
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18 years+ - NCT05693844RecruitingPhase 1/Phase 2
MSLN CAR T cell therapy for advanced solid tumors
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
Beijing, Beijing MunicipalityAges 18–75 - NCT06250036RecruitingPhase 2
Immunotherapy before surgery for MMRd stomach cancer
This trial tests two immunotherapy drugs, zimberelimab and domvanalimab, given before surgery for people with a specific type of stomach cancer (called MMRd/MSI-H). The goal is to see if these drugs can shrink the tumor and improve outcomes.
Cambridge, CambridgeshireAges 18 years+ - NCT07228247RecruitingPhase 1/Phase 2
Study of HMPL-A251 for advanced HER2-positive cancers
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06031584RecruitingPhase 1/Phase 2
Testing BL-M07D1 for HER2-positive or low solid tumors
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT05989425RecruitingPhase 2
Surufatinib before surgery for advanced thyroid cancer
This trial tests whether the drug Surufatinib, given before surgery, can shrink locally advanced or metastatic thyroid cancer. It's a targeted therapy that blocks blood vessels that feed tumors, and is given as a pill to see if it makes the cancer easier to remove.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Palo Alto, CaliforniaAges 18 years+ - NCT07395804Recruiting
How darolutamide works for advanced prostate cancer in Germany
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
LocationsAges 18 years+ - NCT07396584RecruitingPhase 1/Phase 2
HMPL-A580 for advanced or metastatic solid tumors
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
Orange, CaliforniaAges 18 years+ - NCT07606612RecruitingPhase 1
Testing SI-B036 in Advanced Solid Tumors
This early-stage trial tests a new drug called SI-B036 in patients with advanced cancers that have spread or cannot be completely removed by surgery. The goal is to understand how safe the drug is and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT05671822RecruitingPhase 2
Study of targeted drugs for HER2-positive advanced stomach cancer
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07359404Enrolling by invitationPhase 2
Sacituzumab Govitecan plus Bevacizumab for metastatic TNBC
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05889247Recruiting
Blood test guided monitoring for advanced lung cancer treatment
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
Hillerød, Region HAges Any age - NCT07591155RecruitingPhase 1
Testing BL-ARC002 for advanced solid tumors
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06227156RecruitingPhase 2
Targeted drug for HER2-positive castration-resistant prostate cancer
This trial tests a new drug called Disitamab Vedotin for men with advanced prostate cancer that is no longer responding to hormone therapy. The drug targets a protein called HER2 on cancer cells to try to shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06960395RecruitingPhase 1
Study of VIR-5525 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Scottsdale, ArizonaAges 18 years+ - NCT05978492RecruitingPhase 1
Study of TXN10128 for advanced solid tumors
This trial is testing a new drug, TXN10128, for people with advanced solid tumors that have stopped responding to other treatments. It may be an option if standard treatments haven't worked or aren't suitable.
Seongnam-si, Gyeonggi-doAges 19 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,872 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.